EGFR-TKI 已成为 EGFR 突变晚期非小细胞肺癌（NSCLC）患者的标准治疗方案[1]，然而，约 2%~5% 的初治 EGFR 突变晚期 NSCLC 患者合并原发 MET 扩增，且接受 EGFR-TKI ...

非小细胞肺癌的驱动基因EGFR有个不是很常见的突变位点——20号外显子插入突变，这个突变类型占所有EGFR突变的6%左右，使用第一代和第二代EGFR靶向药治疗EGFR基因的20外显子插入突变，治疗应答率仅为10%左右，中位无进展生存时间大概为1到3个 ...

Patients with non-small cell lung cancer of the adenocarcinoma ... and be considered for first-line treatment with an EGFR tyrosine kinase inhibitor if a mutation is identified.

During a live event, Alexander I. Spira, MD, PhD, and participants NGS testing practices and the rationale behind their ...

Panelists discuss how; the patient case presents a 47-Year-Old Woman with EGFR-mutated Advanced/Metastatic NSCLC. The patient ...

Rezivertinib outperforms gefitinib as first-line treatment in EGFR-mutated locally advanced or metastatic non-small-cell lung ...

In their most recent work, they found that the EGFR isoform D produced by sensitive tumors had certain characteristics that ...

Adding the VEGF inhibitor ramucirumab (Cyramza) to the EGFR inhibitor osimertinib (Tagrisso) slowed progression of untreated EGFR-positive non-small cell lung ... in the first-line setting in ...

Tagrisso was linked to higher cardiac risks in patients with EGFR-mutant NSCLC, including a four-fold rise in cardiac events ...

EMA committee recommends extension of marketing authorisation for Janssen-Cilag’s subcutaneous Rybrevant to treat advanced EGFR-mutated NSCLC: Beerse, Belgium Tuesday, February ...